The interim report summarizes Kemira's financial performance from January to March 2013. Key points include:
- Organic revenue growth of 3% and operative EBIT increased 9% to EUR 42.2 million due to cost savings and sales volume growth.
- Earnings per share decreased to EUR 0.01 mainly due to a EUR 23 million write-down related to divesting shares in a joint venture.
- Net debt decreased to EUR 357 million due to proceeds from divesting food/pharmaceutical and joint venture businesses.